Basitrasin

Basitrasin
Nama sistematis (IUPAC)
	(4R)-4-[(2S)-2-({2-[(1S)-1-amino-2-metilbutil]- 4,5-dihidro-1,3-tiazol-5-yl}formamido)-4-metilpentanamido]-4-{[(1S)- 1-{[(3S,6R,9S,12R,15S,18R,21S)- 18-(3-aminopropil)-12-benzil-15-(butan-2-il)-3-(karbamoilmetil)- 6-(karboksimetil)-9-(1H-imidazol-5-ilmetil)-2,5,8,11,14,17,20- heptaokso-1,4,7,10,13,16,19-heptaazasiklopentakosan-21-il]karbamoil}- 2-metilbutil]karbamoil}asam butanoat
Data klinis
Nama dagang	Baciguent, Baciim, dll
AHFS/Drugs.com	monograph
Kat. kehamilan	D(AU)
Status hukum	Harus dengan resep dokter (S4) (AU) OTC (US)
Rute	Topikal, intramuskular, diteteskan melalui mata
Pengenal
Nomor CAS	1405-87-4
Kode ATC	D06AX05 J01XX10, R02AB04, S01AA32, QA07AA93
PubChem	CID 439542
DrugBank	DB00626
ChemSpider	10481985
UNII	58H6RWO52I
KEGG	D00128
ChEBI	CHEBI:28669
ChEMBL	CHEMBL1200558
Data kimia
Rumus	C66H103N17O16S
SMILES	eMolecules & PubChem
	InChI InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36?,37?,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1 ; Key:CLKOFPXJLQSYAH-NVOBBBONSA-N ;

Basitrasin adalah salah satu antibiotik polipeptida. Obat ini merupakan campuran peptida siklik terkait yang diproduksi oleh bakteri Bacillus licheniformis, yang pertama kali diisolasi dari varietas "Tracy I" (ATCC 10716) pada tahun 1945.^[1] Peptida ini mengganggu bakteri gram-positif dengan mengganggu dinding sel dan sintesis peptidoglikan.

Obat ini terutama digunakan sebagai sediaan topikal, karena dapat menyebabkan kerusakan ginjal jika digunakan secara internal.^[2] Umumnya aman bila digunakan secara topikal, namun dalam kasus yang jarang terjadi dapat menyebabkan reaksi hipersensitivitas, alergi, atau anafilaksis, terutama pada orang yang alergi terhadap neomisin.^[3]^[4]

Sejarah

Kegunaan dalam Medis

Mekanisme Kerja

Sintesis

Komposisi

Dalam Budaya Masyarakat

Terdapat sebuah kontroversi yakni klaim bahwa basitrasin adalah penghambat protein disulfida isomerase, hal ini kemudian dibantah oleh penelitian in vitro.^[5]^[6]

Referensi

^ Originally grouped under B. subtilis, but nomenclature has since changed. See Podstawka A. "Bacillus licheniformis Tracy I | DSM 603, ATCC 10716, CCM 2181, IFO 12199, NBRC 12199, NCIB 8874, FDA BT1 | BacDiveID:686". bacdive.dsmz.de (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 7 February 2022. Diakses tanggal 7 February 2022.
^ Zintel HA, Ma RA (October 1949). "The absorption, distribution, excretion and toxicity of bacitracin in man". The American Journal of the Medical Sciences. 218 (4): 439–445. doi:10.1097/00000441-194910000-00012. PMID 18140540.
^ Spann CT, Taylor SC, Weinberg JM (July 2004). "Topical antimicrobial agents in dermatology". Disease-a-Month. 50 (7): 407–421. doi:10.1016/j.disamonth.2004.05.011. PMID 15280871.
^ Trookman NS, Rizer RL, Weber T (March 2011). "Treatment of minor wounds from dermatologic procedures: a comparison of three topical wound care ointments using a laser wound model". Journal of the American Academy of Dermatology. 64 (3 Suppl): S8–15. doi:10.1016/j.jaad.2010.11.011 . PMID 21247665.
^ Karala AR, Ruddock LW (June 2010). "Bacitracin is not a specific inhibitor of protein disulfide isomerase". The FEBS Journal. 277 (11): 2454–62. doi:10.1111/j.1742-4658.2010.07660.x. PMID 20477872.
^ Weston BS, Wahab NA, Roberts T, Mason RM (November 2001). "Bacitracin inhibits fibronectin matrix assembly by mesangial cells in high glucose". Kidney International. 60 (5): 1756–64. doi:10.1046/j.1523-1755.2001.00991.x . PMID 11703593.

[1] Originally grouped under B. subtilis, but nomenclature has since changed. See Podstawka A. "Bacillus licheniformis Tracy I | DSM 603, ATCC 10716, CCM 2181, IFO 12199, NBRC 12199, NCIB 8874, FDA BT1 | BacDiveID:686". bacdive.dsmz.de (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 7 February 2022. Diakses tanggal 7 February 2022.

[Zintel-2] Zintel HA, Ma RA (October 1949). "The absorption, distribution, excretion and toxicity of bacitracin in man". The American Journal of the Medical Sciences. 218 (4): 439–445. doi:10.1097/00000441-194910000-00012. PMID 18140540.

[3] Spann CT, Taylor SC, Weinberg JM (July 2004). "Topical antimicrobial agents in dermatology". Disease-a-Month. 50 (7): 407–421. doi:10.1016/j.disamonth.2004.05.011. PMID 15280871.

[4] Trookman NS, Rizer RL, Weber T (March 2011). "Treatment of minor wounds from dermatologic procedures: a comparison of three topical wound care ointments using a laser wound model". Journal of the American Academy of Dermatology. 64 (3 Suppl): S8–15. doi:10.1016/j.jaad.2010.11.011 . PMID 21247665.

[5] Karala AR, Ruddock LW (June 2010). "Bacitracin is not a specific inhibitor of protein disulfide isomerase". The FEBS Journal. 277 (11): 2454–62. doi:10.1111/j.1742-4658.2010.07660.x. PMID 20477872.

[6] Weston BS, Wahab NA, Roberts T, Mason RM (November 2001). "Bacitracin inhibits fibronectin matrix assembly by mesangial cells in high glucose". Kidney International. 60 (5): 1756–64. doi:10.1046/j.1523-1755.2001.00991.x . PMID 11703593.

[1]

[2]

[3]

[4]

[5]

[6]